Scott Nelson on FastWave’s Mission to Transform IVL Treatments

Key Points for the Article

• Scott Nelson is the co-founder and CEO of FastWave Medical, a startup transforming intravascular lithotripsy (IVL) treatments.
• FastWave’s electric IVL (E-IVL) and laser IVL (L-IVL) systems address challenges with calcified artery disease.
• The company’s recent $19M funding round highlights market confidence in their approach.
• FastWave’s collaboration with physicians ensures innovation meets clinical needs.
• Upcoming clinical trials aim to advance patient outcomes.

Scott Nelson, co-Founder and CEO of FastWave Medical, is on a mission to redefine the treatment of calcified artery disease. With a focus on addressing unmet clinical needs, FastWave Medical is developing next-generation intravascular lithotripsy technology designed to improve both physician experience and patient outcomes.

“Our goal is to empower interventionalists across the world with next-level IVL therapies,” says Scott Nelson. “This round of stage-appropriate funding is a testament to the confidence the market has in our approach.”

What Sets FastWave Apart?

FastWave Medical’s approach to IVL is rooted in solving the challenges presented by calcified artery disease, causes 1 in 4 deaths in the U.S., and is growing due to aging, diabetes, and other health issues. Traditional treatments often fall short, leaving physicians searching for better solutions.

FastWave’s IVL systems are designed to deliver improved procedural feedback and ease of use with an enhanced balloon catheter. FastWave’s rupture-resistance balloon includes a reduced crossing profile and an optimized shaft for better pushability. Additionally, FastWave’s systems deliver 360-degree sonic pressure with more consistent energy at a faster rate compared to existing IVL technologies.

Milestones That Prove FastWave’s Potential

Since its formation in 2021, FastWave Medical has achieved significant milestones:

• Securing seven patents from the USPTO.
• Conducting a first-in-human study of the E-IVL system, which delivered positive 30-day results.
• Completing an oversubscribed $19M funding round, led by physician investors who believe in the company’s mission.

A Physician-Driven Vision

FastWave’s strength lies in its collaboration with medical thought leaders, including interventional cardiologists, vascular surgeons, and radiologists. These partnerships ensure the company’s devices are tailored to meet the real-world needs of end-users.

“FastWave Medical has all the hallmarks of a company poised for significant growth and impact,” says Dr. Steven Kum, Chief Medical Officer of M&L Healthcare Investments. “Their commitment to evidence-based development aligns perfectly with our investment philosophy.”

What’s Next for FastWave Medical?

Looking ahead, the company is set to embark on key clinical trials, including:

• A first-in-human coronary study for the L-IVL system.
• An IDE peripheral pivotal trial for the E-IVL system.
• An early feasibility study (EFS) for the L-IVL system.

These steps will bring FastWave closer to its goal of addressing gaps in current IVL technology, such as shorter procedural time, enhanced durability, and better crossability.

A Bright Future for IVL Treatments

FastWave’s journey is not just about technology—it’s about improving lives. With their deep cardiovascular expertise FastWave’s team is on track to make a lasting impact on the cardiovascular field.

“We are beyond thrilled to partner with physician-led investors who see the clinical promise and commercial viability of both our IVL systems,” Nelson states. “FastWave’s pace of innovation stands out on every metric.”

FastWave Medical is not just building better devices; it’s building a future where physicians have the right tools to treat their patients, who in turn receive the care they deserve. Stay tuned for more milestones as this innovative company continues its mission to transform IVL treatments.